Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

/PRNewswire/ - Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate,...

Related Keywords

United States ,Vancouver ,British Columbia ,Canada ,Karim Lalji ,Jeff Millard ,Cystic Fibrosis Foundation ,Microbion Corporation ,Chief Scientific ,Chief Executive ,Orphan Drug Act ,Orphan Drug ,Fast Track ,Qualified Infectious Disease Product ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,